<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03398837</url>
  </required_header>
  <id_info>
    <org_study_id>JBT101-SSc-002</org_study_id>
    <nct_id>NCT03398837</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis</brief_title>
  <acronym>RESOLVE-1</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corbus Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corbus Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing
      the efficacy and safety of lenabasum for the treatment of diffuse cutaneous systemic
      sclerosis (SSc). Approximately 354 subjects will be enrolled in this study at about 60 sites
      in North America, Europe, Australia, and Asia. The planned duration of treatment with study
      drug is 52 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of lenabasum compared to placebo for the change from baseline in modified Rodnan skin score.</measure>
    <time_frame>Change from baseline through study completion, up to 1 year.</time_frame>
    <description>mRSS evaluates a subject's skin thickness on a 4 point scale for 17 surface anatomic areas: 0 = normal skin; 1 = mild thickness; 2 = moderate thickness; 3 = severe thickness with inability to pinch skin into fold. The individual values of the 17 surface areas are summed to define the total skin score with a maximum score of 51.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of lenabasum compared to placebo for the change from baseline in Health Assessment Questionnaire - Disability Index.</measure>
    <time_frame>Change from baseline through study completion, up to 1 year.</time_frame>
    <description>It includes 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). The individual scores of the eight sections are summed and divided by 8. The result is the disability index or functional disability index. A higher score indicates more functional disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of lenabasum compared to placebo for the American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis score.</measure>
    <time_frame>American College of Rheumatology Combined Response Index score through study completion, up to 1 year.</time_frame>
    <description>The ARC CRISS exponential algorithm determines the predicted probability of improvement from baseline, incorporating change in mRSS, FVC % predicted, physician and patient global assessments, and HAQ-DI. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of lenabasum compared to placebo for the change from baseline in forced vital capacity.</measure>
    <time_frame>Change from baseline through study completion, up to 1 year.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">354</enrollment>
  <condition>Diffuse Cutaneous Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenabasum 5 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenabasum 20 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenabasum 5 mg</intervention_name>
    <description>Subjects will receive lenabasum 5 mg twice daily.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenabasum 20 mg</intervention_name>
    <description>Subjects will receive lenabasum 20 mg twice daily.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Subjects will receive placebo twice daily.</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. ≥ 18 years of age at the time Informed Consent is signed.

          2. Diffuse cutaneous SSc (skin thickening on upper arms, upper legs, or trunk).

          3. Disease duration ≤ 6 years from the first non-Raynaud's symptom.

          4. No new or increased doses of immunosuppressive medications within 8 weeks prior to
             Screening.

        Key Exclusion Criteria:

          1. Unstable SSc or SSc with end-stage organ involvement at Screening or Visit 1.

          2. Any of the following values for laboratory tests at Screening:

               1. A positive pregnancy test in women of childbearing potential;

               2. Hemoglobin &lt; 9 g/dL for males and &lt; 8 g/dL for females;

               3. Neutrophils &lt; 1.0 ×10^9/L;

               4. Platelets &lt; 75 ×10^9/L;

               5. Creatinine clearance &lt; 50 mL/min according to the Modification of Diet in Renal
                  Disease (MDRD) Study equation;

               6. Aspartate aminotransferase or alanine aminotransferase &gt; 2.0 × upper limit of
                  normal.

          3. Any medical condition or concurrent medical therapies at Screening or Visit 1,
             including a history of non-compliance with medical treatments, that may put the
             subject at greater safety risk, influence response to study product, or interfere with
             study assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Spiera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Clinical Medicine, Weill Cornell Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chris Denton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Experimental Rheumatology and Consultant Rheumatologist and Centre Head, Royal Free Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott Constantine, MS</last_name>
    <phone>617-963-0707</phone>
    <email>sscpatients@corbuspharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara White, MD</last_name>
    <email>physicians@corbuspharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pacific Arthritis Care Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omar Aly</last_name>
    </contact>
    <investigator>
      <last_name>Daniel E Furst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Nicholus</last_name>
    </contact>
    <investigator>
      <last_name>Lorinda Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mallory Crow Adams</last_name>
      <phone>303-724-8403</phone>
    </contact>
    <investigator>
      <last_name>Aryeh Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hopkins University, Scleroderma Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwendolyn Leatherman</last_name>
    </contact>
    <investigator>
      <last_name>Laura Hummers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center (BUMC) - General Clinical Research Unit (GCRU)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Stratton</last_name>
    </contact>
    <investigator>
      <last_name>Robert Simms, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Clinical Research Center, Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Chen, RN</last_name>
    </contact>
    <investigator>
      <last_name>Vivien M Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Yusov</last_name>
    </contact>
    <investigator>
      <last_name>Robert Spiera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System - PCAM, Dept. of Rheumatology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Neubauer</last_name>
    </contact>
    <investigator>
      <last_name>Nora Sandorfi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Arthritis and Autoimmunity Center, Falk Clinic</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Ivanco</last_name>
    </contact>
    <investigator>
      <last_name>Robyn T Domsic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Scleroderma</keyword>
  <keyword>cannabinoid receptor type 2 agonist</keyword>
  <keyword>anabasum</keyword>
  <keyword>JBT-101</keyword>
  <keyword>lenabasum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

